ESSA Pharma downgraded by Piper Sandler with a new price target
$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler downgraded ESSA Pharma from Overweight to Neutral and set a new price target of $2.00 from $15.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | Buy → Hold | Jefferies | |
| 11/4/2024 | Outperform → Perform | Oppenheimer | |
| 11/4/2024 | $15.00 → $2.00 | Overweight → Neutral | Piper Sandler |
| 6/26/2023 | $17.00 | Outperform | Oppenheimer |
| 8/17/2021 | $36.00 → $22.00 | Outperform | Oppenheimer |
Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy data showed the single-agent enzalutamide control arm performing better than historical controls and similar to the combination of masofaniten and enzalutamide and therefore, unlikely to achieve the primary endpoint of the study Additional clinical studies with masofaniten including the combination study with abiraterone acetate and apalutamide as well as the remaining investigator sponsored trials will also
Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 88% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. After 15.2 months of follow up, median time to PSA progression and radiographic progression free survival have not yet been reached. SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 13, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pha
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 11, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 9:10 a.m. ET in New York, NY. David R. Parkinson, President and Chief Executive Officer, Peter Virsik, Chief Operating Officer and Executive Vice President, and David S. Wood, Chief Financial Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed in the Investors/Events
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
Oppenheimer analyst Leland Gershell maintains ESSA Pharma (NASDAQ:EPIX) with a Outperform and maintains $17 price target.
ESSA Pharma (NASDAQ:EPIX) reported its Q1 earnings results on Tuesday, February 13, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Earnings ESSA Pharma beat estimated earnings by 17.65%, reporting an EPS of $-0.14 versus an estimate of $-0.17. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.09 which was followed by a 0.36% increase in the share price the next day. ** Listen to the earnings announcement yourself by clicking here. ** To track all earnings releases for ESSA Pharma visit their earnings calendar here. This article was generated by Benzinga's automated content engine and review
ESSA Pharma (NASDAQ:EPIX) has outperformed the market over the past 5 years by 3.09% on an annualized basis producing an average annual return of 15.65%. Currently, ESSA Pharma has a market capitalization of $297.22 million. Buying $1000 In EPIX: If an investor had bought $1000 of EPIX stock 5 years ago, it would be worth $2,060.30 today based on a price of $6.73 for EPIX at the time of writing. ESSA Pharma's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engin
SC 13G - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G - ESSA Pharma Inc. (0001633932) (Subject)
Jefferies downgraded ESSA Pharma from Buy to Hold
Oppenheimer downgraded ESSA Pharma from Outperform to Perform
Piper Sandler downgraded ESSA Pharma from Overweight to Neutral and set a new price target of $2.00 from $15.00 previously
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios. "Lauren's cross-functional expertise in guiding products through all stages of commercial development adds a valuable perspective that complements the sk
On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations well beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 5, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 14, 2024 /C
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 14, 2024 /P
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
8-K - ESSA Pharma Inc. (0001633932) (Filer)
8-K - ESSA Pharma Inc. (0001633932) (Filer)
10-Q - ESSA Pharma Inc. (0001633932) (Filer)